Paradoxically, JPM tends to be more newsworthy for established drug/biotech companies—who often issue annual EPS guidance at the conference—than it is for development-stage companies.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”